Treatment of tuberculosis and optimal dosing schedules

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Thorax

• Publication date

  2010-12-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/thx.2010.148585PMID 21169286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.

  2015cited by this paper
• Tuberculosis (HIV-negative people).

  2011cited by this paper
• Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.

  2010cited by this paper
• Intermittent or daily short course chemotherapy for tuberculosis in children: Meta-analysis of randomized controlled trials

  2010cited by this paper
• Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis.

  2010cited by this paper
• Scottish Intercollegiate Guidelines Network

  2010cited by this paper
• Thorax

  2009cited by this paper
• Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

  2009cited by this paper
• A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.

  2009cited by this paper
• Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review.

  2009cited by this paper
• Prevalence of drug-resistant Mycobacterium tuberculosis in patients under intermittent or daily treatment.

  2009cited by this paper
• Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs

  2009cited by this paper
• Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis

  2009cited by this paper
• Risk factors for new pulmonary tuberculosis patients failing treatment under the Revised National Tuberculosis Control Programme, India.

  2009cited by this paper
• Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis

  2009cited by this paper
• Long term efficacy of DOTS regimens for tuberculosis: systematic review

  2008cited by this paper
• Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.

  2008cited by this paper
• Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil

  2008cited by this paper
• Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

  2008cited by this paper
• Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin

  2007cited by this paper
• Advances in the Treatment of Tuberculosis

  2007cited by this paper
• Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model

  2007cited by this paper
• Treatment outcomes of patients with HIV and tuberculosis.

  2007cited by this paper
• Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

  2006cited by this paper
• Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis.

  2006cited by this paper
• Progress of DOTS in global tuberculosis control.

  2006cited by this paper
• Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

  2005cited by this paper
• Toman's Tuberculosis--Case Detection, Treatment, and Monitoring: Questions and Answers

  2005cited by this paper
• Toman's tuberculosis: case detection, treatment, and monitoring.

  2005cited by this paper
• Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

  2005cited by this paper
• Efficient Intermittent Rifapentine-Moxifloxacin-Containing Short-Course Regimen for Treatment of Tuberculosis in Mice

  2005cited by this paper
• Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

  2004cited by this paper
• A nested case-control study on treatment-related risk factors for early relapse of tuberculosis.

  2004cited by this paper
• Isoniazid Pharmacokinetics-Pharmacodynamics in an Aerosol Infection Model of Tuberculosis

  2004cited by this paper
• The search for new sterilizing anti-tuberculosis drugs.

  2004cited by this paper
• What is the 'right' dose of rifampin?

  2003cited by this paper
• The curious characteristics of pyrazinamide: a review.

  2003cited by this paper
• Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.

  2003cited by this paper
• Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis.

  2003cited by this paper
• The hunt for the elusive surrogate marker of sterilizing activity in tuberculosis treatment.

  2003cited by this paper
• Directly observed treatment for tuberculosis

  2003cited by this paper
• Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis

  2003cited by this paper
• Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.

  2002cited by this paper
• Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan.

  2001cited by this paper
• A Concurrent Comparison of Intermittent ( Twice-Weekly ) Isoniazid plus Streptomycin and Daily Isoniazid plus PAS in the Domiciliary Treatment of Pulmonary Tuberculosis TUBERCULOSIS CHEMOTHERAPY

  2001cited by this paper
• Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy.

  2001cited by this paper
• Postantibiotic Effects of Antituberculosis Agents Alone and in Combination

  2001cited by this paper
• Treatment of isoniazid-resistant tuberculosis in southeastern Texas.

  2001cited by this paper
• Fully intermittent dosing with drugs for treating tuberculosis in adults.

  2001cited by this paper
• Fully intermittent dosing with drugs for tuberculosis.

  2000cited by this paper
• Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.

  2000cited by this paper
• Role of individual drugs in the chemotherapy of tuberculosis.

  2000cited by this paper
• Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand.

  1999cited by this paper
• Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.

  1999cited by this paper
• Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications.

  1999cited by this paper
• How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.

  1998cited by this paper
• Two-year follow-up of directly-observed intermittent regimens for smear-positive pulmonary tuberculosis in China.

  1998cited by this paper
• Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis.

  1998cited by this paper
• Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection.

  1996cited by this paper
• Directly observed therapy for tuberculosis: history of an idea.

  1995cited by this paper
• Eleven years of community-based directly observed therapy for tuberculosis.

  1995cited by this paper
• Directly observed treatment of tuberculosis.

  1993cited by this paper
• Directly observed treatment of tuberculosis. We can't afford not to try it.

  1993cited by this paper
• Bacteriological investigations for short-course chemotherapy under the tuberculosis programme in two districts of India.

  1993cited by this paper
• The Postantibiotic Effect: A Review of in Vitro and in Vivo Data

  1991cited by this paper
• Qualitative and quantitative drug-susceptibility tests in mycobacteriology.

  1988cited by this paper
• Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions.

  1988cited by this paper
• Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: Final report

  1986cited by this paper
• Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study.

  1986cited by this paper
• Controlled clinical trial of 4 short-couse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis.

  1983cited by this paper
• Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council.

  1982cited by this paper
• Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis second reportthe results up to 24 months

  1982cited by this paper
• Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis.

  1981cited by this paper
• Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment.

  1980cited by this paper
• Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment.

  1980cited by this paper
• Basic mechanisms of chemotherapy.

  1979cited by this paper
• Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils.

  1978cited by this paper
• Clinical Pharmacokinetics of Rifampicin

  1978cited by this paper
• Serum rifampicin concentration related to dose size and to the incidence of the 'flu' syndrome during intermittent rifampicin administration.

  1977cited by this paper
• Tuberculosis in a rural population of South India: a five-year epidemiological study.

  1974cited by this paper
• Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions.

  1973cited by this paper
• CHLORAMPHENICOL-RESISTANT SALMONELLA TYPHI

  1973cited by this paper
• Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions.

  1973cited by this paper
• Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report.

  1973cited by this paper
• Kinetic studies on rifampicin

  1972cited by this paper
• Rifampicin, a general review.

  1971cited by this paper
• Ten-year results during the introduction of chemotherapy for tuberculosis.

  1971cited by this paper
• Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks.

  1971cited by this paper
• Four regimens of streptomycin plus pyrazinamide in retreatment: East African-British Medical Research Council investigation.

  1970cited by this paper
• A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis.

  1969cited by this paper
• In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens.

  1968cited by this paper
• Toxicity of pyrazinamide, administered once weekly in high dosage, in tuberculous patients.

  1968cited by this paper
• Advances in the treatment of tuberculosis.

  1967cited by this paper
• Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model.

  1967cited by this paper
• A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India.

  1966cited by this paper
• A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS.

  1966cited by this paper
• ACONCURRENT COMPARISON OF INTERMITTENT (TWICE-WEEKLY) ISONIAZID PLUS STREPTOMYCIN AND DAILY ISONIAZID PLUS PAS IN THE DOMICILIARY TREATMENT OF PULMONARY TUBERCULOSIS; TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS.

  1964cited by this paper
• Self-administration of medicaments. A review of published work and a study of the problems.

  1962cited by this paper

• Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial

  2023cites this paper
• Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings

  2022cites this paper
• The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance

  2020cites this paper
• Effectiveness of interventions for reducing TB incidence in countries with low TB incidence: a systematic review of reviews

  2019cites this paper
• Indian healthcare through the global health ethics lens: despite some gains, have we truly progressed?

  2019cites this paper
• How can gastro-intestinal tuberculosis diagnosis be improved? A prospective cohort study

  2019cites this paper
• Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: therapeutic assessment in a murine model of tuberculosis infection.

  2019cites this paper
• Resisting Resistance

  2019cites this paper
• Updates in the Treatment of Active and Latent Tuberculosis

  2018cites this paper
• SC Abolishes Thrice Weekly Dose; Restores Daily Dose Protocol in TB Across India

  2017cites this paper
• Understanding the Role of TGF-b1 in Interstitial Lung Disease Using A Multi-Scale Systems Biology Approach

  2017cites this paper
• Applying Optimization Algorithms to Tuberculosis Antibiotic Treatment Regimens

  2017cites this paper
• Applying Optimization Algorithms to Tuberculosis Antibiotic Treatment Regimens

  2017cites this paper
• Rifampicin-induced immune allergic reaction

  2017cites this paper
• A review of computational and mathematical modeling contributions to our understanding of Mycobacterium tuberculosis within-host infection and treatment.

  2017cites this paper
• Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis

  2016cites this paper
• Fully Intermittent, Thrice-Weekly Dose of Anti-Tuberculosis Drugs; Their Efficacy under Routine Program Conditions of India

  2016cites this paper
• Comparison of Drug Concentration of Isoniazid and Rifampicin between Daily and Intermittent Anti-Tubercular (ATT) Regimen, in Children treated for Tuberculosis

  2016cites this paper
• Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy

  2016cites this paper
• Drug Sensitivity Pattern among Category – I Relapse Cases of Pulmonary Tuberculosis and Its Correlation with Pre-treatment Sputum and Radiological Status .

  2016cites this paper
• A Prospective Study of Tuberculosis Drug Susceptibility in Sabah, Malaysia, and an Algorithm for Management of Isoniazid Resistance

  2015cites this paper
• In silico evaluation and exploration of antibiotic tuberculosis treatment regimens

  2015cites this paper
• Classic reaction kinetics can explain complex patterns of antibiotic action

  2015cites this paper
• Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model

  2015cites this paper
• Tuberculosis: which drug regimen and when.

  2015cites this paper
• Clinical research in the treatment of tuberculosis: current status and future prospects.

  2015cites this paper
• India should screen all tuberculosis patients for drug resistant disease at diagnosis

  2015cites this paper
• A multi-scale approach to designing therapeutics for tuberculosis.

  2015cites this paper
• 1 1 A Multi-scale Approach to 2 Designing Therapeutics for Tuberculosis 3 4 5 6

  2015cites this paper
• Molecular typing of drug-susceptible-, mono-resistant-, multi-drug resistant- (MDR) and extensively-drug resistant- (XDR) Mycobacterium tuberculosis strains in Johannesburg.

  2015cites this paper
• [Childhood tuberculosis].

  2015cites this paper
• Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update

  2014cites this paper
• Minding the gaps in tuberculosis research.

  2014cites this paper
• Intermittent versus daily therapy for treating tuberculosis in children.

  2014cites this paper
• The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy.

  2014cites this paper
• The effect of fortified food, e'pap, on oral candidiasis in adult TB patients attending clinics in Alexandra, Johannesburg, South -Africa

  2014cites this paper
• Résistance à la fl uoroquinolone de Mycobacterium tuberculosis. Qu'avons-nous appris ?

  2014cites this paper
• Prescription patterns for tuberculosis treatment and adherence to treatment guidelines: a population‐based study in Taiwan

  2014cites this paper
• Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment

  2014cites this paper
• Challenges of tuberculosis management in high and low prevalence countries in a mobile world

  2014cites this paper
• Childhood tuberculosis: a concern of the modern world

  2014cites this paper
• Fluoroquinolone resistance in Mycobacterium tuberculosis. What have we learnt?

  2014cites this paper
• Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients

  2014cites this paper
• Looking Back to the Future: Predicting in Vivo Efficacy of Small Molecules versus Mycobacterium tuberculosis

  2014cites this paper
• Unfinished battle with childhood tuberculosis: is it curable with less drugs and shorter duration?

  2013cites this paper
• Tuberculous lymphadenopathy: a multicentre operational study of 6-month thrice weekly directly observed treatment.

  2013cites this paper
• Advances in tuberculosis 2011–2012

  2013cites this paper
• High relapse rate in RNTCP: An increasing concern and time to intervene

  2013cites this paper
• Current issues in the management of tuberculosis in Europe.

  2013cites this paper
• Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program

  2013cites this paper
• DOT, S, or DOTS?

  2012cites this paper
• INVITED REVIEW SERIES: TUBERCULOSIS: CURRENT STATE OF KNOWLEDGE

  2012cites this paper
• Feasibility of a Fixed-Dose Regimen of Pyrazinamide and Its Impact on Systemic Drug Exposure and Liver Safety in Patients with Tuberculosis

  2012cites this paper
• Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines

  2012cites this paper
• Tuberculose : infection et maladie

  2012cites this paper
• Biosafety in Laboratories using Nonhuman Primates

  2012cites this paper
• Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals

  2012cites this paper
• Diagnosis and management of TB in children: an update

  2011cites this paper